BYSI BeyondSpring Inc.

17.03
+1.44  (+9%)
Previous Close 15.59
Open 15.85
Price To Book 21.56
Market Cap 474,948,069
Shares 27,888,906
Volume 46,132
Short Ratio
Av. Daily Volume 42,571
Stock charts supplied by TradingView

NewsSee all news

  1. BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification

    - DSMB Reviewed Over 500 Patients' Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC - - Data Continue to Support Plinabulin's Immune

  2. BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program

    NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer

  3. BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients

    NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies,

  4. BeyondSpring Files 2019 Annual Report on Form 20-F

    NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today

  5. BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update

    - FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - - Initiated NDA Rolling Submission for Plinabulin

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 final data due 2H 2020.
Plinabulin (Trial 105)
Chemotherapy-induced neutropenia (CIN)
Phase 3 final data due 2H 2020.
Plinabulin (Trial 103)
Non small cell lung cancer - refractory
Phase 3 interim analysis expected in 2Q 2020 and final analysis expected in 2H 2020
Plinabulin + TAC (Trial 106)
Chemotherapy-induced neutropenia (CIN)
Phase 1/2 initiation announced October 4, 2018.
Plinabulin + Opdivo +Yervoy
Small-cell lung cancer (SCLC)

Latest News

  1. BeyondSpring Announces Data & Safety Monitoring Board Recommendation for Plinabulin to Continue NSCLC Phase 3 Dublin-3 Study Without Modification

    - DSMB Reviewed Over 500 Patients' Data in Second Interim Analysis to Assess Overall Benefit / Risk with Plinabulin in Second- and Third-Line, EGFR Wild-Type NSCLC - - Data Continue to Support Plinabulin's Immune

  2. BeyondSpring E-Poster Presented at 2020 ASCO Virtual Scientific Program

    NEW YORK, June 02, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer

  3. BeyondSpring Granted New U.S. Patent for Plinabulin to Treat Severe Chemotherapy-Induced Neutropenia from Taxane in Cancer Patients

    NEW YORK, May 13, 2020 (GLOBE NEWSWIRE) -- BeyondSpring (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies,

  4. BeyondSpring Files 2019 Annual Report on Form 20-F

    NEW YORK, April 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today

  5. BeyondSpring Reports Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update

    - FDA Submission to Change the Primary Endpoint for Study 106 Phase 3 into an Industry First and Robust Clinical Measure to Evaluate Superiority in CIN - - Initiated NDA Rolling Submission for Plinabulin

  6. FDA Submission to Change the Primary Endpoint into an Industry First and Robust Clinical Measure for Superiority of CIN Phase 3 Study

    NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a New York-based global biopharmaceutical company focused on the development of innovative immuno-oncology

  7. BeyondSpring to Host Fourth-Quarter and Full-Year 2019 Financial Results and Operational Update Conference Call on April 30, 2020

    NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today

  8. BeyondSpring Initiates New Drug Application Rolling Submission for Plinabulin in China for Chemotherapy-Induced Neutropenia

    - Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years - - Targeting CIN After All Chemotherapies in All Cancer Types in Combination with All G-CSFs - - Strong

  9. BeyondSpring's Plinabulin May Prevent Tissue Iron Overload in Anemic Cancer Patients Receiving Chronic Blood Transfusions During Chemotherapy

    - New Data to be Presented at NCCN 2020 Annual Conference - NEW YORK, March 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused

  10. BeyondSpring Files for Patent Protection on BPI-002 for the Treatment of Viral Infections Including COVID-19

    NEW YORK, March 11, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer

  11. BeyondSpring's Plinabulin Stimulates Both the Adaptive and Innate Immune System in Cancer Patients

    NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer

  12. BeyondSpring Appoints Pharma Veterans Drs. Daniel Zabrowski and Ramon Mohanlal to Company's Board of Directors

    NEW YORK, Jan. 23, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer

  13. BeyondSpring Strengthens Executive Rank for Pipeline Expansion and Commercialization Readiness in China

    Dr. James Tonra Promoted to Chief Scientific Officer Roland Liu Named Chief Commercial Officer for China Subsidiary NEW YORK, Jan. 06, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or

  14. BeyondSpring Publishes Report on Benefits and Mechanism of Plinabulin in Reducing Neutropenia with Multiple Chemotherapies

    NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the peer

  15. BeyondSpring Provides Third-Quarter 2019 Operational and Financial Results Update

    Preparing to Submit NDA in China for Chemotherapy-Induced Neutropenia ("CIN") in Q1 2020 Plinabulin's Anti-Cancer and CIN Prevention Mechanism Published in Peer Reviewed Journals NEW YORK, Dec. 18,

  16. BeyondSpring to Host Third-Quarter 2019 Financial Results and Operational Update Conference Call on December 18, 2019

    NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today

  17. BeyondSpring's Study 106 Phase 3 Superior Trial Design Combining Plinabulin with Pegfilgrastim Versus Pegfilgrastim Alone for Chemotherapy-Induced Neutropenia Presented at ASH 2019 Annual Meeting

    NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the

  18. BeyondSpring's Abstracts on Clinical Evidence for Bone Marrow Stem Cell Protection as Plinabulin's Mechanism of Action for CIN Accepted at American Society of Hematology's 2019 Annual Meeting

    NEW YORK, Dec. 09, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that two

  19. BeyondSpring's Single-Blinded Design (for Patients Only) of Phase 3 Study 103 (DUBLIN-3) Prevented Premature Patient Drop-Out: Data Accepted for Presentation at SITC 2019

    NEW YORK, Nov. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the

  20. BeyondSpring Appoints Gregg Russo as Senior Vice President, Human Resources

    NEW YORK, Nov. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the

  21. BeyondSpring Announces Proposed Public Offering of Ordinary Shares

    NEW YORK, Oct. 24, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of

  22. Cell Journals Publishes BeyondSpring's New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation

    NEW YORK, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that Cell Press

  23. BeyondSpring Presents Novel Trial Design for DUBLIN-3 Study BPI-2358-103 at ESMO Congress 2019

    NEW YORK, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative immune-oncology cancer therapies, today announced that the

  24. BeyondSpring's Plinabulin Continues to Build on Superior Product Profile in Breast Cancer Trial for Neutropenia Prevention

    NEW YORK, Sept. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced that a Company abstract with

  25. BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results

    - To Submit New Drug Applications ("NDAs") in China for Both Non-Small Cell Lung Cancer ("NSCLC") and Chemotherapy-Induced Neutropenia ("CIN") in Q1 2020 - - To Submit NDAs in the United States ("U.S.") for Both

  26. BeyondSpring, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / September 18, 2019 / BeyondSpring, Inc. (NASDAQ:BYSI) will be discussing their earnings results in their 2019 Second Quarter Earnings to be held on September 18, 2019 at 8:00 AM Eastern

  27. BeyondSpring to Host Second-Quarter 2019 Financial Results and Operational Update Conference Call on September 18, 2019

    NEW YORK, Sept. 11, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today

  28. BeyondSpring's Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer

    NEW YORK, Sept. 10, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company's novel

  29. BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    NEW YORK, Sept. 06, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the "Company" or "BeyondSpring") (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced

  30. BeyondSpring's Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia

    NEW YORK, Aug. 23, 2019 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, today announced the results of its head-to-head